Privilège Ventures

Privilège Ventures is an early-stage venture capital firm based in Lugano, Switzerland, and authorized by FINMA, the Swiss financial market supervisor. It invests in founders building HealthTech, MedTech and Longevity companies across Switzerland and Europe, backing what it describes as deep technology and breakthrough science in human health.

The firm's flagship investment vehicle holds stakes in more than 20 portfolio companies. Rather than operating as a blind pool, the vehicle is structured for visibility: named portfolio companies, their traction and their portfolio weights are disclosed to investors. This approach - transparency around holdings in place of aggregate reporting - is a distinguishing feature of the firm's fund design at a stage where such disclosure is uncommon.

Alongside capital, Privilège Ventures provides operational support covering strategy, governance, operations, execution and growth. The team describes itself as experienced on both sides of the table, as entrepreneurs and as investors, and states that it stays close to founders while deferring to their leadership and vision. Partnerships are framed around trust, transparency and aligned ambition, with the intent of supporting companies as they mature from early stages onward.